Exploration of the benefits and resistance mechanisms of immunotherapy based on PD-L1 expression, circulating tumor DNA and T-cell receptor profiles in advanced gastric cancer.

In the CPS 1–4 subgroup, numerical differences in PFS were observed with C + PD-1i + anti-angiogenic therapy (mPFS 10.3 months) versus C + PD-1i (mPFS 7.4 months) or C alone (mPFS 7.5 months), but these differences did not reach statistical significance ( p > 0.05, Fig. 2 c).

also in 111,027 other papers